ADA’s Big Week, Lilly and AstraZeneca Among the Headlines
Week Of June 6 - June 12, 2026
ADA 2026 (the American Diabetes Association conference) wrapped up this week, and the readouts included new data as well as new details on some that already reported results. Lilly’s retatrutide filled in the detail behind its already-reported 28% weight loss, adding benefits in knee osteoarthritis pain and sleep apnea, while Novo’s CagriSema looked ordinary right next to it. Boehringer’s survodutide posted deep visceral and liver fat reductions. AstraZeneca’s oral pill elecoglipron met every endpoint, yet some analysts still called it “underwhelming” because a smaller rival posted bigger numbers the same week. In the Trial Spotlight, I go into how to read a met-its-endpoints-but-called-disappointing readout, and why cross-trial weight-loss comparisons are tricky. In the Mechanism Explained, I cover a pattern that ran through the whole conference: why the same drug produces less weight loss in people with diabetes than in people with obesity, and the kidney-level reason behind it. Also this week: oral Wegovy’s UK approval and Gan & Lee’s Phase 3 progress out of China.
🔥 THIS WEEK’S KEY DEVELOPMENTS
Novo Nordisk’s CagriSema meets primary endpoints across Phase 3 REIMAGINE trials.
Novo Nordisk announced that its investigational drug CagriSema met primary endpoints across three Phase 3 trials in the REIMAGINE program for adults with type 2 diabetes. In the 68-week REIMAGINE 2 trial, CagriSema 2.4 mg/2.4 mg demonstrated a statistically significant 1.91% reduction in HbA1c and a 14.2% reduction in bodyweight, compared to a 1.75% HbA1c reduction and 10.2% weight reduction for semaglutide 2.4 mg. The REIMAGINE 1 and 3 trials also showed significant reductions versus placebo, with the 2.4 mg/2.4 mg dose achieving HbA1c reductions of 1.8% and 2.33% and bodyweight reductions of 13.8% and 12.0%, respectively.
Press | Trials: NCT06323174 | NCT06065540 | NCT06323161 | Mechanism: GLP-1 + amylin combination
Retatrutide’s detailed TRIUMPH-1 data add knee OA pain and sleep apnea benefits beyond weight loss.
Eli Lilly announced detailed Phase 3 results for retatrutide from the TRIUMPH-1 trial, where participants on the 12 mg dose lost an average of 28.3% of their body weight (70.3 lbs) over 80 weeks, with 65.3% achieving a BMI below 30. In the TRANSCEND-T2D-1 trial for type 2 diabetes, retatrutide achieved A1C reductions of up to 2.0% and weight loss of up to 16.8% (36.6 lbs) at 40 weeks.
Press | Trials: NCT05929066 | NCT06354660 | Mechanism: triple agonist
Boehringer’s Phase 3 survodutide data reveals 63% liver fat reduction.
In a pre-specified analysis from a sub-study of the Phase III SYNCHRONIZE-1 trial, Boehringer Ingelheim’s survodutide achieved up to a 34% reduction in visceral fat and up to a 63.1% reduction in liver fat after 76 weeks. The main 76-week trial met its primary endpoints, showing up to 16.6% weight loss from baseline, while lean mass loss accounted for no more than 10.8% of the change in total tissue mass at the highest dose.
Press | Trials: NCT06066515 | NCT06309992 | Mechanism: glucagon/GLP-1 dual agonist
📰 PRESS
Novo Nordisk secures UK approval for daily oral Wegovy pill.
Press | Mechanism: GLP-1
Pfizer’s monthly berobenatide posts up to 15.9% weight loss, heads toward 10 Phase 3 trials.
Press | Trials: NCT07575932 | Mechanism: GLP-1 receptor agonist
Gan & Lee’s bofanglutide meets endpoints in a China Phase 3 obesity study and a US Phase 2.
Press | Trials: NCT06737042 | Mechanism: GLP-1 RA
Lilly’s oral orforglipron tops Novo’s oral semaglutide in first head-to-head diabetes trial.
Press | Mechanism: GLP-1
Kailera presents positive ribupatide bridging data at ADA.
Press | Mechanism: GLP-1/GIP dual agonist
Tolerability stands out in Roche and Zealand’s amylin obesity prospect petrelintide.
Press | Mechanism: amylin analog
Study: Semaglutide 2 mg matches tirzepatide on blood sugar, tops on weight loss.
Press | Mechanism: GLP-1 agonist
💡 TRIAL SPOTLIGHT
Educational spotlight selected by editors
Met Every Endpoint, Still Called ‘Underwhelming’: How to Read AstraZeneca’s Oral GLP-1 Data
AstraZeneca’s once-daily oral GLP-1 receptor agonist, elecoglipron, delivered a clean, positive, yet context-dependent result in its Phase 2b program, prompting a move to Phase 3. In the 310-patient VISTA trial for obesity, the small-molecule pill achieved a solid 11.8% average weight loss at 36 weeks (versus about 0.3% on placebo), with a curve that had not yet plateaued, suggesting further benefit was possible. The 406-patient SOLSTICE trial in type 2 diabetes also succeeded, showing a strong 1.9% reduction in HbA1c and 7.7% weight loss. The lower weight-loss figure in the diabetes cohort is an expected outcome of incretin biology, a phenomenon detailed in this week’s Mechanism Explained. Safety and tolerability were consistent with the GLP-1 class: about 93% of participants completed the study, and gastrointestinal-driven discontinuations stayed low at roughly 2 to 4%.
The strategic debate ignited at the ADA 2026 conference, where these data were presented, hinges entirely on the choice of comparator. Judged in isolation, elecoglipron’s performance was a clear success, meeting all endpoints. However, at the same meeting, rival Structure Therapeutics reported that its oral GLP-1, aleniglipron, achieved roughly 15% placebo-adjusted weight loss at 36 weeks, creating a challenging side-by-side comparison that led some analysts to label AstraZeneca’s results “relatively underwhelming.” This highlights a crucial lesson in trial interpretation: while headlines often carelessly compare weight-loss percentages, factors like trial duration are critical. Comparing elecoglipron’s 36-week, non-plateaued result to the longer, 64-to-72-week registrational data for drugs like oral semaglutide or orforglipron is misleading.
AstraZeneca’s decision to advance elecoglipron from the back of the current oral-pill pack is a strategic bet, not on a best-in-class Phase 2 number, but on future potential. The company is likely banking on the signal that more weight loss may be achievable with longer dosing and an optimized titration schedule in Phase 3. This positions the program as a long-term platform play, potentially for combinations within AstraZeneca’s broad cardiometabolic portfolio, rather than a sprint to win on monotherapy efficacy alone. The key question is whether this hopeful signal can translate into competitive registrational data in a crowded field.
ClinicalTrials.gov: NCT06579092 (VISTA, obesity) | NCT06579105 (SOLSTICE, type 2 diabetes)
🔬 MECHANISM EXPLAINED
Understanding the science behind the therapeutics
Why Diabetes Blunts the Scale: The Glucosuria Offset Behind Smaller Weight Loss (Example drugs: Elecoglipron, Semaglutide, Tirzepatide)
A consistent pattern on display at ADA 2026 and in historical data is that people with type 2 diabetes (T2D) lose less weight on incretin drugs than people with obesity but without diabetes. This was seen again this week with AstraZeneca’s oral GLP-1, elecoglipron, which drove 10.5% weight loss in the VISTA obesity trial but 7.7% in the SOLSTICE T2D trial at the same dose. This isn’t a sign of drug failure but an expected, mechanistically understood difference that makes direct cross-trial comparisons misleading. The pattern holds for every major incretin: semaglutide produced about 15% loss in obesity (STEP-1) versus about 10% in T2D (STEP-2), and tirzepatide showed a similar gap between its SURMOUNT-1 (about 21-22%) and SURMOUNT-2 (about 15%) trials.
The primary driver of this weight-loss gap is a phenomenon called the glucosuria offset. In poorly controlled T2D, high blood sugar overwhelms the kidneys’ ability to reabsorb glucose, causing calories to be spilled into the urine, a process known as glucosuria that passively removes energy from the body. When an incretin drug effectively lowers blood glucose toward normal levels, this urinary calorie-spilling stops. The body begins retaining those calories that were previously being lost, and this retained energy partially counteracts the weight loss caused by the drug’s primary effect on appetite. Since people without diabetes do not have glucosuria to begin with, they experience the full, unblunted weight-loss effect of the drug.
This physiological offset is multifactorial, with other elements contributing to the observed difference. Patients in T2D trials are often on background medications that can promote weight gain, such as insulin or sulfonylureas, which are absent from obesity-only trials. Factors like longer disease duration and different baseline metabolic profiles in the T2D population are also recognized as smaller contributors to the attenuated weight-loss response. Understanding this context is important for reading clinical data accurately. The smaller weight loss in a diabetes trial does not mean the drug is less effective; it reflects a different physiological starting point, where patients gain a profound glycemic benefit alongside still-meaningful weight reduction.
🆕 NEWLY REGISTERED TRIALS (1 in last week)
NNC0662-0419 Phase 2 trial comparing different dose-escalation strategies in participants with obesity (Novo Nordisk, n=230)
[Weight Loss/Efficacy]
Trials: NCT07639021 | Mechanism: Triple GLP-1/GIP/glucagon agonist
This newsletter compiles publicly available information from press releases, news sources, and trial registries. Not investment advice.
Get in touch: Reply to this email, leave a comment on the post, or find me on X @GLP1observer. Explore the GLP-1 dashboard at glp1.bio1up.com.